文献速递复苏、休克与脓毒症呼吸衰竭与机械通气重症综合管理与镇静镇痛

重型SARS-CoV-2感染患者血栓风险高:多中心前瞻性队列研究

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study.
PubMed 文献 · Intensive Care Med · 2020-05-04
一句话结论COVID-19相关ARDS患者尽管接受抗凝治疗,血栓并发症仍高发(主要为肺栓塞),且显著多于非COVID-19 ARDS患者,作者认为可能应建议更高的抗凝目标。

本研究在法国一家三级医院的两个中心的4个ICU中,前瞻性纳入2020年3月3日至31日因COVID-19导致ARDS的患者150例(122例男性,中位年龄63岁,SAPSII 49分),并采用倾向性评分匹配与非COVID-19 ARDS患者(n=145)比较血栓栓塞事件。150例患者中共诊断64例临床相关血栓并发症,主要为肺栓塞(16.7%);接受连续肾脏替代治疗的29例中28例(96.6%)发生管路凝血;12例接受ECMO支持的患者中2例发生3次离心泵血栓闭塞(8%)。多数患者(>95%)D-二聚体和纤维蛋白原升高,无患者发生弥散性血管内凝血;血管性血友病因子活性、抗原及凝血因子VIII显著升高,57例受检者中50例(87.7%)狼疮抗凝物阳性。与非COVID-19 ARDS患者比较,COVID-19 ARDS患者血栓并发症显著更多,主要为肺栓塞(11.7% vs 2.1%,p<0.008),两组凝血参数显著不同。结论认为,尽管接受抗凝治疗,COVID-19相关ARDS患者仍出现大量危及生命的血栓并发症,因此可能应建议比通常重症患者更高的抗凝目标。

要点

  • COVID-19相关ARDS患者尽管接受抗凝治疗,150例中仍诊断64例临床相关血栓并发症,主要为肺栓塞(16.7%)。
  • 接受连续肾脏替代治疗的29例中28例(96.6%)发生管路凝血;12例ECMO支持患者中2例发生3次离心泵血栓闭塞(8%)。
  • 倾向性评分匹配比较显示,COVID-19 ARDS患者(n=77)血栓并发症显著多于非COVID-19 ARDS患者(n=145),主要为肺栓塞(11.7% vs 2.1%,p<0.008)。
  • 多数患者(>95%)D-二聚体和纤维蛋白原升高,无患者发生弥散性血管内凝血;57例受检者中50例(87.7%)狼疮抗凝物阳性。
  • 作者认为,尽管抗凝治疗,血栓并发症仍高发,可能应建议比通常重症患者更高的抗凝目标。

适用人群与场景

  • 2020年3月3日至31日转诊至法国一家三级医院两个中心的4个ICU、因COVID-19导致ARDS的患者(150例,122例男性,中位年龄63[53;71]岁,SAPSII 49[37;64]分)。
  • 对照为非COVID-19 ARDS患者(n=145),用于倾向性评分匹配比较。

红旗征与不能漏的情况

  • 接受连续肾脏替代治疗的患者中管路凝血高发(29例中28例,96.6%)。
  • 接受ECMO支持的患者中可发生离心泵血栓闭塞(12例中2例发生3次,8%)。
  • 临床相关血栓并发症主要为肺栓塞(150例中16.7%)。

研究设计与关键结果

  • 研究类型为多中心前瞻性队列研究,纳入4个ICU(两个中心)的150例COVID-19相关ARDS患者,并采用倾向性评分匹配与非COVID-19 ARDS患者(n=145)比较。
  • 150例患者中共诊断64例临床相关血栓并发症,主要为肺栓塞(16.7%)。
  • 接受连续肾脏替代治疗的29例中28例(96.6%)发生管路凝血;12例ECMO支持患者中2例发生3次离心泵血栓闭塞(8%)。
  • 多数患者(>95%)D-二聚体和纤维蛋白原升高,无患者发生弥散性血管内凝血;血管性血友病因子活性、血管性血友病因子抗原及凝血因子VIII显著升高,57例受检者中50例(87.7%)狼疮抗凝物阳性。
  • 与非COVID-19 ARDS患者(n=145)比较,COVID-19 ARDS患者(n=77)血栓并发症显著更多,主要为肺栓塞(11.7% vs 2.1%,p<0.008),两组凝血参数显著不同。

证据类型、等级与局限

  • 证据类型:多中心前瞻性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,尽管接受抗凝治疗,COVID-19相关ARDS患者仍出现大量危及生命的血栓并发症,因此可能应建议比通常重症患者更高的抗凝目标。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Little evidence of increased thrombotic risk is available in COVID-19 patients. Our purpose was to assess thrombotic risk in severe forms of SARS-CoV-2 infection.

METHODS: All patients referred to 4 intensive care units (ICUs) from two centers of a French tertiary hospital for acute respiratory distress syndrome (ARDS) due to COVID-19 between March 3rd and 31st 2020 were included. Medical history, symptoms, biological data and imaging were prospectively collected. Propensity score matching was performed to analyze the occurrence of thromboembolic events between non-COVID-19 ARDS and COVID-19 ARDS patients.

RESULTS: 150 COVID-19 patients were included (122 men, median age 63 [53; 71] years, SAPSII 49 [37; 64] points). Sixty-four clinically relevant thrombotic complications were diagnosed in 150 patients, mainly pulmonary embolisms (16.7%). 28/29 patients (96.6%) receiving continuous renal replacement therapy experienced circuit clotting. Three thrombotic occlusions (in 2 patients) of centrifugal pump occurred in 12 patients (8%) supported by ECMO. Most patients (> 95%) had elevated D-dimer and fibrinogen. No patient developed disseminated intravascular coagulation. Von Willebrand (vWF) activity, vWF antigen and FVIII were considerably increased, and 50/57 tested patients (87.7%) had positive lupus anticoagulant. Comparison with non-COVID-19 ARDS patients (n = 145) confirmed that COVID-19 ARDS patients (n = 77) developed significantly more thrombotic complications, mainly pulmonary embolisms (11.7 vs. 2.1%, p < 0.008). Coagulation parameters significantly differed between the two groups.

CONCLUSION: Despite anticoagulation, a high number of patients with ARDS secondary to COVID-19 developed life-threatening thrombotic complications. Higher anticoagulation targets than in usual critically ill patients should therefore probably be suggested.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020. PMID: 32367170. doi:10.1007/s00134-020-06062-x

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。